T Cells clinical trials

Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML

This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.

Second bone marrow transplant with gentler chemotherapy

This trial studies a “reduced intensity” second transplant using donated blood-forming cells, for people whose first transplant did not fully and reliably restart blood production. It aims to improve donor blood cell growth while using a less harsh conditioning approach.

Skin sample study to create future cell therapies

This study collects skin cells from people with certain long-term conditions (or specific genetic disorders). Researchers use the cells to try to build new treatments for human disease and disability in the future.

Blood Cell Collection Study for Immune and Blood Disorders

This study collects blood cells and bone marrow from people with immune system or blood disorders, and from healthy volunteers. Researchers will study these cells and may convert them into special stem cells (iPS cells) to better understand diseases and develop treatments.

Study of blood cancers’ natural course and next treatment needs

This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.

Harvesting Cancer Cells for Experimental Treatment

This trial collects immune cells from cancer patients or healthy volunteers to develop new experimental cancer treatments. Researchers will take a sample of your tumor or blood cells, grow them in the lab, and study how to use them to fight your cancer.

Understanding kidney cancer genes in families

This research study helps doctors understand inherited kidney cancers and related conditions that run in families. Researchers collect medical information and blood samples to identify genetic causes and improve how these conditions are diagnosed and treated.

Study of thyroid lumps and thyroid cancer

This study looks at people who have or may have thyroid nodules (lumps in the thyroid gland in your neck) or thyroid cancer, as well as family members who may have inherited a higher risk. It aims to better understand and diagnose these thyroid problems.

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Study drug for ER-positive, HER2-negative cancers after treatment

This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.

Planning advance care after stem cell transplant

This study tests a program that helps stem cell transplant survivors plan their future care with their doctors. It uses a website and a patient navigator to guide you through conversations about your goals and values.

Belinostat trial for neuroendocrine cancer based on genetics

This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.

CAR T cell therapy study for children with DIPG brain tumor

This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.

Study of a new drug combo for untreated DLBCL

This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.

Gene therapy for solid tumors that returned after treatment

This trial tests a new type of gene therapy that uses your own immune cells (called myeloid cells) engineered to produce a protein (IL-12) to fight your cancer. It is for people with solid tumors that have not responded to standard treatments.

Optic nerve sheath changes after therapy in giant cell arteritis

This study looks at how quickly the optic nerve sheath (the protective layer around the eye nerve) changes after starting treatment for giant cell arteritis (GCA), a condition that causes inflammation in blood vessels. It aims to see if these changes can help doctors monitor the disease and guide treatment.

New cancer drug combo for advanced cervical cancer

This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL

This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.

Evaluation of a Point-of-Care, AI-Powered Spectroscopy Device for Triage of Suspicious Vulvar Lesions: A Pilot Study

BEX101 for B-cell non-Hodgkin's lymphoma

This trial tests a new treatment called BEX101 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.

A study of a new drug for advanced solid tumors

This trial tests a new drug called petosemtamab (MCLA-158) for people with advanced solid tumors that have not responded to other treatments. The drug is designed to target and kill cancer cells. You may be able to participate if you meet the health and cancer history requirements.

Follow-on treatment study for dabrafenib and trametinib

This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.

Study of a new drug for relapsed small cell lung cancer

This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.